The evolving landscape of pulmonary arterial hypertension clinical trials

PHA Canada
Nov 26, 2022
1 min read

Updated: Nov 7, 2024

In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance requires longer studies with more participants. Given that PAH is a rare disease, finding large numbers of participants is a problem. Innovative trial designs offer new options while still providing good data.

Read the original journal article

Recent Posts

Racial and ethnic equity in PAH clinical trials

Looking at the racial and ethnic breakdown of patients with PAH and patients who take part in clinical trials, the authors conclude that the goal of equitable representation has not yet been reached.

Air pollution may worsen PAH

Air pollution is known to be bad for heart and lung diseases, but this study looked at whether it affected pulmonary arterial hypertension (PAH) in particular. They followed a cohort of patients for a

Kettlebell exercise training was safe and effective for PAH patients

A small study of patients with stable pulmonary arterial hypertension (PAH) were randomly assigned to either no exercise program or an exercise program using kettlebells three days per week for 8 week

Comments